Immunofluorescence
Immunofluorescence analysis of HuvEc cells, using eEF2 (Phospho-Thr56) Antibody. The picture on the right is treated with the synthesized peptide.Western blot
Immunohistochemistry analysis of paraffin-embedded human breast carcinoma, using eEF2 (Phospho-Thr56) Antibody. The picture on the right is treated with the synthesized peptide.Western blot analysis of extracts from NIH-3T3 cells treated with Serum 10% 30', using eEF2 (Phospho-Thr56) Antibody. The lane on the right is treated with the synthesized peptide| Product Name | Rabbit anti-eEF2 (Phospho-Thr56) polyclonal antibody |
|---|---|
| Antibody Type | Primary Antibodies |
| Immunogen | The antiserum was produced against synthesized peptide derived from human eEF2 around the phosphorylation site of Thr56. |
| Modification | p-Thr56 |
| Clonality | Polyclonal |
|---|---|
| Host Species | Rabbit |
| Tested Applications | WBIHCIFELISA |
| WB:1:500~1:1000 IHC:1:50~1:100 IF:1:100~1:500 ELISA:1:10000 |
|
| Species Reactivity | HumanMouseRat |
| Concentration | 1mg/ml |
| Purification | Affinity purified |
| Gene Symbol | EEF2 |
|---|---|
| Gene Synonyms | EEF2 EF-2 EF2 Elongation factor 2 |
Immunofluorescence
Immunofluorescence analysis of HuvEc cells, using eEF2 (Phospho-Thr56) Antibody. The picture on the right is treated with the synthesized peptide.
Western blot
Immunohistochemistry analysis of paraffin-embedded human breast carcinoma, using eEF2 (Phospho-Thr56) Antibody. The picture on the right is treated with the synthesized peptide.Western blot analysis of extracts from NIH-3T3 cells treated with Serum 10% 30', using eEF2 (Phospho-Thr56) Antibody. The lane on the right is treated with the synthesized peptide| Application Notes | WB:1:500~1:1000 IHC:1:50~1:100 IF:1:100~1:500 ELISA:1:10000 |
|---|
| Form | Liquid |
|---|---|
| Storage Instructions | store at -20°C. Avoid repeated freeze / thaw cycles |
| Storage Buffer | Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. |
